Regeneron Pharmaceuticals on Track for Largest Percent Decrease Since June 2023 — Data Talk
Regeneron Pharmaceuticals, Inc. (REGN) is currently at $910.44, down $25.77 or 2.75%
--Would be lowest close since Jan. 10, 2024, when it closed at $906.16
--On pace for largest percent decrease since June 27, 2023, when it fell 8.71%
--Currently down three of the past four days
--Currently down two consecutive days; down 3.54% over this period
--Worst two day stretch since the two days ending Nov. 9, 2023, when it fell 3.67%
--Down 5.41% month-to-date
--Up 3.66% year-to-date
--Down 8.35% from its all-time closing high of $993.35 on Feb. 27, 2024
--Up 9.64% from 52 weeks ago (April 13, 2023), when it closed at $830.35
--Down 8.35% from its 52-week closing high of $993.35 on Feb. 27, 2024
--Up 31.48% from its 52-week closing low of $692.45 on July 7, 2023
--Traded as low as $909.80; lowest intraday level since Jan. 11, 2024, when it hit $899.07
--Down 2.82% at today's intraday low; largest intraday percent decrease since Jan. 8, 2024, when it fell as much as 3.52%
--Sixth worst performer in the S&P 500 today
--Second worst performer in the Nasdaq 100 today
All data as of 10:00:42 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 11, 2024 10:19 ET (14:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Apple Earnings: iPhone Growth Forecasts Drive Change in Fair Value
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted